← Back to patent-cliff list
Gallium-68-DOTA-minigastrin
Tier C — Watch / tradeGallium-68-DOTA-minigastrin
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Not applicable
Indications (approved)：Neuroendocrine tumour
Regional status
US
-
EU
Phase II
2021-01-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gallium-68-DOTA-minigastrin?
Approved indications include: Neuroendocrine tumour.
When does the Gallium-68-DOTA-minigastrin patent expire?
No public expiry year is available for Gallium-68-DOTA-minigastrin yet; this page updates once verified.
How do I get a quote for Gallium-68-DOTA-minigastrin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06